Internal and Emergency Medicine

, Volume 4, Issue 2, pp 117–122 | Cite as

Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice

  • Giorgio Costantino
  • Anna Maria Rusconi
  • Pier Giorgio Duca
  • Stefano Guzzetti
  • Ilaria Bossi
  • Marta Del Medico
  • Giuseppina Pisano
  • Mara Bulgheroni
  • Monica Solbiati
  • Raffaello Furlan
  • Nicola Montano
IM - ORIGINAL

Abstract

The aim of the present study was to compare the characteristics of patients referred to our heart failure outpatient clinic with those of patients enrolled in clinical trials on heart failure pharmacological treatment. Thus, we estimated the proportion of patients admitted to our heart failure outpatient clinic who would have been included in randomized controlled trials evaluating the effects of medical treatments on heart failure mortality, published over a 10 years period (1993–2003). Sixteen studies (n = 45276) and 299 consecutive outpatients, were included. On average, only 34% of the outpatients would have been included in at least one of the 16 trials (8–71%). The main reasons for exclusion were: NYHA class (70% were in NYHA class II), ejection fraction (29% had EF > 35%), co-morbidity (51% had co-morbidity, mainly renal failure, COPD, and disthyroidism), age (22% were older than 80 years), and occurrence of a recent acute event (50% experienced an ischemic coronary syndrome, revascularization, pulmonary edema, or stroke in the prior 6 months). These results underline the crucial role of patient selection in clinical trials, raising uncertainties about the complete applicability of trial results to clinical practice.

Keywords

Heart failure Randomized controlled trials Evidence-based medicine 

Notes

Acknowledgment

This work was partially supported by a FIRST 2006 Grant from the University of Milan (to N.M.)

References

  1. 1.
    The SOLVD Investigators ((1991)) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302Google Scholar
  2. 2.
    Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355PubMedCrossRefGoogle Scholar
  3. 3.
    Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717PubMedCrossRefGoogle Scholar
  4. 4.
    Cohn JN, Rognoni G, for the Valsartan heart failure trial investigators (2001) A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 345:1667–1675Google Scholar
  5. 5.
    Ho KK, Anderson KM, Kannel WB et al (1993) Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88:107–115PubMedGoogle Scholar
  6. 6.
    Levy D, Kenchaiah S, Larson MG et al (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:1397–1402PubMedCrossRefGoogle Scholar
  7. 7.
    MacIntyre K, Capewell S, Steward S et al (2000) Evidence of improving prognosis in heart failure: trends in case-fatality in 66547 patients hospitalized between 1986 and 1995. Circulation 102:1126–1131PubMedGoogle Scholar
  8. 8.
    Baker DW, Einstadter D, Thomas C et al (2003) Mortality trends for 23, 505 medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Hart J 146:258–264CrossRefGoogle Scholar
  9. 9.
    Senni M, Tribouilloy CM, Rodeheffer RJ et al (1999) Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 159:29–34PubMedCrossRefGoogle Scholar
  10. 10.
    Spencer FA, Meyer TE, Goldberg RJ et al (1999) Twenty-year trends (1975–1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 34:1378–1387PubMedCrossRefGoogle Scholar
  11. 11.
    Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259PubMedCrossRefGoogle Scholar
  12. 12.
    Andersson F, Cline C, Ryden-Bergsten T et al (1999) Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing. Pharmacoeconomics 15:535–550PubMedCrossRefGoogle Scholar
  13. 13.
    Hunt SA (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46:e1–e82PubMedCrossRefGoogle Scholar
  14. 14.
    Miller LW (2008) Heart failure: who we treat versus who we study. Cardiol Clin 26:113–125PubMedCrossRefGoogle Scholar
  15. 15.
    Zimmerman M, Mattia J, Posternak M (2002) Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 159:469–473PubMedCrossRefGoogle Scholar
  16. 16.
    Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials. Race, sex, and age-based disparities. JAMA 291:2720–2726PubMedCrossRefGoogle Scholar
  17. 17.
    Van Spall HGC, Toren A, Kiss A et al (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals. A systematic sampling review. JAMA 297:1233–1240PubMedCrossRefGoogle Scholar
  18. 18.
    Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007–2018PubMedCrossRefGoogle Scholar
  19. 19.
    Masoudi FA, Havranek EP, Wolfe P et al (2003) Most hospitalized older persons do no meet the enrollment criteria for clinical trials in heart failure. Am Heart J 146:250–257PubMedCrossRefGoogle Scholar
  20. 20.
    Konstam MA (2000) Progress in heart failure management? Circulation 102:1076–1078PubMedGoogle Scholar
  21. 21.
    Khand A, Gemmel I, Clark AL et al (2000) Is the prognosis of heart failure improving? J Am Coll Cardiol 36:2284–2286PubMedCrossRefGoogle Scholar
  22. 22.
    Cowie MR, Mosterd A, Wood DA (1997) The epidemiology of heart failure. Eur Heart J 18:208–225PubMedGoogle Scholar
  23. 23.
    Ho KK, Pinsky JL, Kannel WB et al (1993) The epidemiology of heart failure: The Framingam study. J Am Coll Cardiol 22(Suppl A):6A–13APubMedCrossRefGoogle Scholar
  24. 24.
    Bellotti P, Badano LP, Acquarone N et al. OSCUR Investigators (2001) Speciality-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Outcome dello Scompenso Cardiaco in relazione all’Utilizzo delle Risorse. Eur Heart J 22:596–604Google Scholar
  25. 25.
    Di Lenarda A, Scherillo M, Maggioni AP et al. TEMISTOCLE Investigators (2003) Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds—the TEMISTOCLE study. Am Heart J 46:E12Google Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  • Giorgio Costantino
    • 1
  • Anna Maria Rusconi
    • 1
  • Pier Giorgio Duca
    • 2
  • Stefano Guzzetti
    • 1
  • Ilaria Bossi
    • 1
  • Marta Del Medico
    • 1
  • Giuseppina Pisano
    • 1
  • Mara Bulgheroni
    • 1
  • Monica Solbiati
    • 1
  • Raffaello Furlan
    • 1
  • Nicola Montano
    • 1
  1. 1.Division of Internal Medicine II, L. Sacco HospitalUniversity of MilanMilanItaly
  2. 2.Medical Statistics, Department of Clinical Sciences, L. Sacco HospitalUniversity of MilanMilanItaly

Personalised recommendations